Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MagnetisMM-2: Elranatamab in Japanese RRMM
NCT04798586Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2021
- Primary completion
- May 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Primary endpoint: Dose Limiting Toxicities at 4 weeks. Started Mar 2021; status: completed.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04798586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04798586.